A detailed history of Qube Research & Technologies LTD transactions in Fibrogen Inc stock. As of the latest transaction made, Qube Research & Technologies LTD holds 64,557 shares of FGEN stock, worth $22,594. This represents 0.0% of its overall portfolio holdings.

Number of Shares
64,557
Holding current value
$22,594
% of portfolio
0.0%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$0.33 - $1.26 $21,303 - $81,341
64,557 New
64,557 $25,000
Q4 2023

Feb 13, 2024

BUY
$0.38 - $0.91 $144 - $344
379 New
379 $0
Q2 2023

Aug 14, 2023

BUY
$2.49 - $20.59 $458,329 - $3.79 Million
184,068 Added 68.31%
453,520 $1.22 Million
Q1 2023

May 15, 2023

BUY
$15.95 - $25.18 $3.89 Million - $6.14 Million
243,955 Added 956.8%
269,452 $5.03 Million
Q4 2022

Feb 14, 2023

BUY
$13.27 - $17.73 $338,345 - $452,061
25,497 New
25,497 $408,000
Q2 2022

Aug 15, 2022

SELL
$7.94 - $12.96 $179,761 - $293,414
-22,640 Closed
0 $0
Q1 2022

May 09, 2022

BUY
$12.02 - $16.79 $272,132 - $380,125
22,640 New
22,640 $272,000
Q1 2020

May 15, 2020

SELL
$23.3 - $45.96 $116,826 - $230,443
-5,014 Closed
0 $0
Q4 2019

Feb 13, 2020

BUY
$34.58 - $48.06 $173,384 - $240,972
5,014 New
5,014 $215,000

Others Institutions Holding FGEN

About FIBROGEN INC


  • Ticker FGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 93,741,200
  • Market Cap $32.8M
  • Description
  • FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...
More about FGEN
Track This Portfolio

Track Qube Research & Technologies LTD Portfolio

Follow Qube Research & Technologies LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Qube Research & Technologies LTD, based on Form 13F filings with the SEC.

News

Stay updated on Qube Research & Technologies LTD with notifications on news.